📣 VC round data is live. Check it out!
- Public Comps
- Meditera
Meditera Valuation Multiples
Discover revenue and EBITDA valuation multiples for Meditera and similar public comparables like Bactiguard, Pentixapharm Holding, Creo Medical Group, Daxor and more.
Meditera Overview
About Meditera
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
Founded
1996
HQ

Employees
N/A
Website
Financials (FY)
EV
$51M
Valuation Multiples
Start free trialMeditera Financials
Meditera reported last fiscal year revenue of $63M and EBITDA of $5M.
In the same fiscal year, Meditera generated $19M in gross profit, $5M in EBITDA, and had net loss of ($203K).
Revenue (LTM)
Meditera P&L
In the most recent fiscal year, Meditera reported revenue of $63M and EBITDA of $5M.
Meditera is unprofitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 7%, and net margin of (0%).
Financial data powered by Morningstar, Inc.
Meditera Stock Performance
Meditera has current market cap of $61M, and enterprise value of $51M.
Market Cap Evolution
Meditera's stock price is $0.64.
Meditera share price decreased by 2.8% in the last 30 days, and by 4.4% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51M | $61M | 3.8% | -2.8% | 0.7% | -4.4% | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeditera Valuation Multiples
Meditera trades at 0.8x EV/Revenue multiple, and 11.3x EV/EBITDA.
EV / Revenue (LTM)
Meditera Financial Valuation Multiples
As of May 23, 2026, Meditera has market cap of $61M and EV of $51M.
Meditera has a P/E ratio of (300.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Meditera Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Meditera Margins & Growth Rates
Meditera grew revenue by 26% and EBITDA by 137% in the last fiscal year.
In the most recent fiscal year, Meditera reported gross margin of 30%, EBITDA margin of 7%, and net margin of (0%).
Meditera Margins
Meditera Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Meditera Operational KPIs
Meditera's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Meditera's Rule of X is 79% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Meditera Competitors
Meditera competitors include Bactiguard, Pentixapharm Holding, Creo Medical Group, Daxor, SMAIO, BATM Advanced Communications, SciBase Holding, Klea, Pulmonx and Cyclopharm.
Most Meditera public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.0x | 3.1x | 15.1x | 18.5x | |||
| 524.9x | — | (3.1x) | — | |||
| 7.7x | 4.2x | (1.4x) | (2.4x) | |||
| 6.1x | 7.2x | — | — | |||
| 5.3x | 4.7x | (55.3x) | (56.6x) | |||
| 0.4x | 0.5x | 2.6x | 3.9x | |||
| 11.9x | 9.6x | (5.9x) | (6.4x) | |||
| 3.4x | — | 14.9x | — | |||
This data is available for Pro users. Sign up to see all Meditera competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Meditera
| When was Meditera founded? | Meditera was founded in 1996. |
| Where is Meditera headquartered? | Meditera is headquartered in Turkey. |
| Is Meditera publicly listed? | Yes, Meditera is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Meditera? | Meditera trades under MEDTR ticker. |
| When did Meditera go public? | Meditera went public in 2021. |
| Who are competitors of Meditera? | Meditera main competitors include Bactiguard, Pentixapharm Holding, Creo Medical Group, Daxor, SMAIO, BATM Advanced Communications, SciBase Holding, Klea, Pulmonx, Cyclopharm. |
| What is the current market cap of Meditera? | Meditera's current market cap is $61M. |
| What is the current revenue of Meditera? | Meditera's last fiscal year revenue is $63M. |
| What is the current revenue growth of Meditera? | Meditera revenue growth (vs. last FY) is 26%. |
| What is the current EV/Revenue multiple of Meditera? | Current revenue multiple of Meditera is 0.8x. |
| Is Meditera profitable? | No, Meditera is not profitable. |
| How many companies Meditera has acquired to date? | Meditera hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Meditera has invested to date? | Meditera hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Meditera
Lists including Meditera
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.